Correlation of Helicobacter pylori infection and cancer ousinhibitor protein phosphatase 2A enhanced expression in patients with gastric cancer

doi:10.3877/cma.j.issn.1674-1358.2017.02.017

Abstract

Abstract:

Objective

To investigate the mechanism of Helicobacter pylori (HP) enhancing the expression of cancer ousinhibitor protein phosphatase 2A (CIP2A) in patients with gastric cancer, and to provide theoretical basis for clinical treatment.

Methods

Total of 80 patients with gastric cancer in our hospital from October 2012 to September 2015 were collected. HP and the gastric cancer cell from tissue samples were cultured, and the changes of CIP2A protein expression were detected by real-time fluorescence quantitative method and Western blot. The correlation of CIP2A expression in gastric cancer tissue and clinicopathological features of Hp infection were analyzed. The prognostic factors of patients with gastric cancer were analyzed by Cox proportional hazards regression model.

Results

The positive expression rates of CIP2A protein in gastric cancer tissues, paracancerous tissues and normal gastric mucosal tissues were 66.3%, 25% and 10%, respectively, with significant difference (χ² = 37.29, P = 0.025). The expression levels of CIP2A protein in gastric cancer tissue of tumor infiltrating extent and lymph node metastasis were significantly high. The infection rate of HP in patient of gastric cancer group (67.5%) was significantly higher than that of the control group (40.0%), with significant difference (χ²= 5.136, P = 0.023). The positive expression rate of CIP2A protein were 11.5% and 88.9% in gastric cancer group with non-HP infection and with HP infection, with significant difference (χ² = 8.428, P = 0.005). The prognosis of patients were significantly correlated with the clinical pathological features which include lymph node metastasis, tumor infiltration depth and expression of CIP2A protein in gastric cancer tissue.

Conclusions

HP infection rate of patients with gastric cancer was higher than that of the normal population; CIP2A protein expression was an independent prognostic factor in patients with gastric cancer.

Key words: Gastric cancer, Cancer ousinhibitor protein phosphatase 2A, Helicobacter pylori, Prognosis factor

Fei Chen, Jun Li. Correlation of Helicobacter pylori infection and cancer ousinhibitor protein phosphatase 2A enhanced expression in patients with gastric cancer[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2017, 11(02): 185-189.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2017.02.017

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2017/V11/I02/185

Figures/Tables 2

References 25

1	赵永勋. 幽门螺杆菌感染增强CIP2A在胃癌中的表达及其临床意义[D]. 兰州大学, 2014.
2	陈晓兵. 胃癌患者幽门螺杆菌感染情况与肿瘤恶性程度的相关性研究[J]. 海南医学院学报,2017,23(4):475-477.
3	刘为，杨志平. 根除幽门螺旋杆菌联合叶酸疗法治疗疣状胃炎患者的前景[J]. 中国民康医学,2016,28(5):85-86.
4	张姣莉，李国庆. EGRF, CIP2A及c-Myc在胃癌细胞增殖中相互作用的关系[J]. 现代医药卫生,2017,33(3):393-395.
5	黎敏. MACC1和CIP2A蛋白表达的相关性及其与胃癌预后的关系[J]. 中国现代医学杂志,2016,26(21):25-29.
6	师海蓉. CIP2A shRNA真核表达载体的构建及其对胃癌细胞增殖的抑制作用[J]. 基础医学与临床,2015,35(2):162-166.
7	张彭. 埃索美拉唑联合抗生素治疗幽门螺杆菌阳性萎缩性胃炎患者的效果及安全性观察[J]. 中国民康医学,2016,28(21):26-28.
8	张晓雪. 非甾体抗炎药相关性胃炎患者幽门螺杆菌感染对其胃黏膜功能的影响[J]. 中国民康医学,2016,28(24):13-14.
9	王丽昆，杨娟，李仲铭, 等. 三联,四联疗法及Boulardii酵母菌在幽门螺杆菌根除治疗中的疗效评估[J]. 昆明医科大学学报,2015,36(2):102-105.
10	李世通，杨兵. 幽门螺杆菌流行病学及耐药性研究现状[J]. 临床医药实践,2016,25(1):53-55.
11	李红伟，李多杰，柴大敏, 等. CIP2A和CK2β蛋白在食管鳞状细胞癌中的表达及其与预后的关系[J]. 上海交通大学学报(医学版),2016,36(2):200-205.
12	Wu Y, Gu TT, Zheng PS. CIP2A cooperates with H-Ras to promote epithelial-mesenchymal transition in cervical-cancer progression[J]. Can Let,2015,356(2):646-655.
13	Guo Z, Liu D, Su Z. CIP2A mediates prostate cancer progression via the c-MYC signaling pathway[J]. Tumor Biol,2015,36(8):6587.
14	Khanna A, Rane JK, Kivinummi KK, et al. CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations[J]. Oncotarget,2015,5(23):19661-19670.
15	Peng B, Lei N, Chai Y, et al. CIP2A regulates cancer metabolism and CREB phosphorylation in non-small cell lung cancer[J]. Mol Biosyst,2015,11(1):105-114.
16	Barragán E, Chillón MC, Castelló-Cros R, et al. CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia[J]. Haematologica,2015,100(5):183-185.
17	Liu CY, Hu MH, Chia-Jung H, et al. Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells[J]. Oncotarget,2016,7(8):9135-9149.
18	Lucas CM, Harris RJ, Holcroft AK, et al. Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients[J]. Leukemia,2015,29(7):1514-1523.
19	Liu J, Meng W, Zhang X, et al. CIP2A is associated with multidrug resistance in cervical adenocarcinoma by a P-glycoprotein pathway[J]. Tumor Biol,2016,37(2):2673-2682.
20	Xiao X, He Z, Cao W, et al. Oridonin inhibits gefitinib-resistant lung cancer cells by suppressing EGFR/ERK/MMP-12 and CIP2A/Akt signaling pathways[J]. Int J Oncol,2016,48(6):2608-2618.
21	Lucas C M, Milani M, Butterworth M, et al. High CIP2A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-XL in chronic myeloid leukemia[J]. Leukemia,2016,30(6):1273-1281.
22	胡茜，刘昆. CIP2A及c-Myc在宫颈癌组织中的表达及相关性分析[J]. 重庆医学,2015,13(8):1072-1074.
23	Cristóbal I, Rojo F, Madoz-Gurpide J, et al. The cross-talk between Wnt/β-Catenin and CIP2A/Plk1 signaling in prostate cancer: promising therapeutic implications[J]. Mol Cell Bio,2016,36(12):13-16.
24	Peng X, Jie Y, Jin H, et al. CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine[J]. Oncotarget,2016,7(12):14831-14840.
25	陈翠霞，杨小敏，祝晓芬, 等. CIP2A与c-myc在喉癌组织中的表达及临床意义[J]. 热带医学杂志,2016,16(6):728-731.

病理特征		例数	CIP2A表达阳性	χ²值	P值
性别				0.504	0.478
	男	49	31（63.3）
	女	31	22（70.9）
年龄				0.334	0.563
	< 60岁	38	25（65.7）
	≥ 60岁	42	25（59.5）
肿瘤直径				0.024	0.877
	< 40 mm	41	28（68.3）
	≥ 40 mm	39	26（66.7）
组织分化				2.399	0.121
	高中分化	38	28（73.7）
	低分化	42	24（57.1）
淋巴结转移				4.581	0.032
	否	34	27（79.4）
	是	46	26（56.5）
侵润程度				6.265	0.012
	T1T2	30	25（83.3）
	T3T4	50	28（56.0）

病理特征		例数	CIP2A表达阳性	χ²值	P值
性别				0.504	0.478
	男	49	31（63.3）
	女	31	22（70.9）
年龄				0.334	0.563
	< 60岁	38	25（65.7）
	≥ 60岁	42	25（59.5）
肿瘤直径				0.024	0.877
	< 40 mm	41	28（68.3）
	≥ 40 mm	39	26（66.7）
组织分化				2.399	0.121
	高中分化	38	28（73.7）
	低分化	42	24（57.1）
淋巴结转移				4.581	0.032
	否	34	27（79.4）
	是	46	26（56.5）
侵润程度				6.265	0.012
	T1T2	30	25（83.3）
	T3T4	50	28（56.0）

单因素Cox回归分析	总生存率
单因素Cox回归分析	相对危险度	95%CI	P值
年龄（岁）（≥ 60 vs. < 60）	1.53	（0.73～3.21）	0.211
性别（男 vs.女）	0.96	（0.53～2.21）	0.897
肿瘤直径大小（mm）（≥ 40 vs. < 40）	1.21	（0.62～2.54）	0.785
组织分化程度（低分化 vs.高中分化）	1.76	（0.67～3.12）	0.223
淋巴结转移（有转移 vs.无转移）	10.06	（3.45～34.62）	0.002
肿瘤浸润深度（T4T3 vs. T2T1）	13.69	（3.86～45.41）	0.001
CIP2A表达（阳性 vs.阴性）	4.65	（2.32～10.12）	0.006
幽门螺杆菌感染（阳性 vs.阴性）	1.86	（0.93～4.35）	0.116

单因素Cox回归分析	总生存率
单因素Cox回归分析	相对危险度	95%CI	P值
年龄（岁）（≥ 60 vs. < 60）	1.53	（0.73～3.21）	0.211
性别（男 vs.女）	0.96	（0.53～2.21）	0.897
肿瘤直径大小（mm）（≥ 40 vs. < 40）	1.21	（0.62～2.54）	0.785
组织分化程度（低分化 vs.高中分化）	1.76	（0.67～3.12）	0.223
淋巴结转移（有转移 vs.无转移）	10.06	（3.45～34.62）	0.002
肿瘤浸润深度（T4T3 vs. T2T1）	13.69	（3.86～45.41）	0.001
CIP2A表达（阳性 vs.阴性）	4.65	（2.32～10.12）	0.006
幽门螺杆菌感染（阳性 vs.阴性）	1.86	（0.93～4.35）	0.116

[1]	Mengsheng Li, Zhongbo Han. High risk and controllable factor of gastric cancer--Helicobacter pylori infection [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2023, 17(03): 145-150.
[2]	Zaibo Zhang, Bingyu Wang, Zhikai Jiao, Bibo Tan. Risk factors for lower extremity deep venous thrombosis after gastric cancer surgery: A Meta-analysis [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(06): 475-480.
[3]	Tiantian Wang, Yuan Wen, Zhen Li, Meihong Ye, Ying Guo, Shuang Ma. The effect of honokiol on the sensitivity of gastric cancer cells to cisplatin chemotherapy by regulating the Nrf2/ARE pathway [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(04): 202-209.
[4]	Xianyong Liu. Molecular mechanisms of gastric Lgr5⁺ stem cells, Mist1⁺ stem cells and Cck2r⁺ stem cells in carcinogenesis [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(03): 183-188.
[5]	Guangjun Zhong, Chunhua Liu, Wansen Zhu, Xiaolei Xu, Zhaojun Wang. Application of conventional MRI combined with different scanning sequences in preoperative staging diagnosis, chemotherapy efficacy and prognosis evaluation of gastric cancer [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 378-382.
[6]	Xiaojuan Han, Jiaqian Xu, Yulan Zhu, Ying Wang, Yuan Li, Jun Feng, Dong Shao. Construction and cell function study of HHLA2-overexpressing gastric cancer cells [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 373-377.
[7]	Xiuyan Sun, Qinglei Xu, Pengtao Ma, Zhiyuan Hu, Chuanzhen Guo, Chenghong Zhu. Correlation analysis of body temperature changes during laparoscopic radical gastrectomy with pressure injury and microenvironment of the compression site [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 480-484.
[8]	Hongyu Xu, Yashuang He. Efficacy of oxycodone and hydromorphone in postoperative analgesia after radical gastrectomy for gastric cancer [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(05): 312-316.
[9]	Liu Yang, Lanqun Qin, Qian Geng, Dongqing Li, Chunjian Qi, Hua Jiang. Predictive value of efficacy and prognosis of soluble immune checkpoints for immunotherapy in patients with gastric cancer [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(05): 305-311.
[10]	Jing Sheng, Yong Mei, Pei Xia, Xiaolin Wang. Clinical study of second-line treatment of advanced gastric cancer with ubenimex combined with irinotecan [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(05): 317-321.
[11]	Xiaoqiong Shi, Guojian Yin. Study on diagnostic accuracy of Helicobacter pylori rapid urease test with different observation time [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(03): 150-154.
[12]	Qing Dong, Fei Ding, Hao Guo, Feng Li. Expression and clinical significance of expression of Nesfatin-1/NUCB2 in early gastric cancer associated with Helicobacter pylori infection [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(07): 783-789.
[13]	Hongtao Wei, Cangjue Pubu, Yangzong Gesang, Yan Li, Wangza Yixi, Peng Li. Helicobacter pylori infection in patients with upper gastrointestinal ulcer in Lhasa: clinical presentation, prognosis, and treatment outcomes [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(06): 662-665.
[14]	Li Wang, Fan Fan, Guodong Chen, Yulan Liu, Liming Zhang. Short- and long-term outcomes of endoscopic submucosal dissection for early gastric cancer and characteristics of early cardiac gastric cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(02): 105-111.
[15]	Jiafeng Wang, Rui Guo, Qianqian Chen, Huikai Li, Bo Ning, Xinpu Yuan, Hua Zhu, Enqiang Linghu. A preliminary exploratory study of the impact of ⁶⁸Ga-NC-BCH combined with PET-CT lymph node immune tracer techniques on preoperative and postoperative clinical decision-making for gastric cancer patients [J]. Chinese Journal of Gastrointestinal Endoscopy(Electronic Edition), 2023, 10(04): 253-257.

Please choose a citation manager

Content to export